A61K 47/6879
The immunoglobulin having two or more different antigen-binding sites
Official title: {the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin}
A61K47/6879 (The immunoglobulin having two or more different antigen-binding sites) appears on 166 US grants and 354 published applications in this corpus.
Search patents in A61K- Granted patents
- 166
- Published applications
- 354
- Assignees
- 189
- Inventors
- 938
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 2 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 2 | 0 |
| 1998 | 1 | 0 |
| 1999 | 3 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 2 |
| 2002 | 1 | 3 |
| 2003 | 2 | 3 |
| 2004 | 1 | 3 |
| 2005 | 0 | 5 |
| 2006 | 2 | 6 |
| 2007 | 1 | 2 |
| 2008 | 3 | 7 |
| 2009 | 2 | 3 |
| 2010 | 4 | 5 |
| 2011 | 3 | 5 |
| 2012 | 1 | 9 |
| 2013 | 3 | 6 |
| 2014 | 8 | 17 |
| 2015 | 7 | 13 |
| 2016 | 11 | 15 |
| 2017 | 10 | 20 |
| 2018 | 4 | 17 |
| 2019 | 10 | 20 |
| 2020 | 8 | 17 |
| 2021 | 14 | 22 |
| 2022 | 10 | 18 |
| 2023 | 15 | 30 |
| 2024 | 11 | 22 |
| 2025 | 10 | 39 |
| 2026 | 10 | 45 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compounds comprising a linker for increasing transcyclooctene stability25 Aug 2026US 12,714,752 B2Tagworks Pharmaceuticals B.V.
- FGF21 compositions for treatment or prevention of neovascularization of the eye and methods therefor16 Jun 2026US 12,653,863 B2Children's Medical Center Corporation
- Conjugation chemistry for catalytic antibody 38C226 May 2026US 12,637,520 B2University of Florida Research Foundation, Inc.
- Anti-FcRH5 antibodies19 May 2026US 12,630,636 B2Genentech, Inc.
- Antibody drug conjugate12 May 2026US 12,622,977 B2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Dual transporters and methods of use8 Oct 2026US 2026/0308269 A1Denali Therapeutics Inc.
- Immunoconjugates containing tnf-alpha and related methods and compositions thereof24 Sep 2026US 2026/0284216 A1Suzhou Fuse Biosciences Limited
- Site-specific orthogonal bioconjugate modality and application thereof24 Sep 2026US 2026/0286332 A1Genequantum Healthcare (Suzhou) Co., Ltd.
- Mutant of antibody variable region, and use thereof27 Aug 2026US 2026/0250416 A1
- Improved linker-payloads for antibody conjugation, pharmaceutical compositions and applications thereof20 Aug 2026US 2026/0241021 A1Obi Pharma, Inc.
Most cited
By later US patents
- Antibodies, and methods for their use111US 5,573,920 ASurface Active Limited · 1996
- Prostaglandin E2 dual variable domain immunoglobulins and uses thereof85US 8,822,645 B2AbbVie Inc. · 2014
- Bispecific molecules for use in inducing antibody dependent effector cell-mediated cytotoxicity54US 5,833,985 AMedarex, Inc. · 1998
- Stable compositions of high-concentration allotype-selected antibodies for small-volume administration51US 9,180,205 B2Immunomedics, Inc. · 2015
- Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy42US 8,481,041 B2IBC Pharmaceuticals, Inc. · 2013